MedPath

Active Biotech AB

Active Biotech AB logo
🇸🇪Sweden
Ownership
Public
Established
1996-01-01
Employees
51
Market Cap
-
Website
http://www.activebiotech.com

Clinical Trials

27

Active:17
Completed:9

Trial Phases

4 Phases

Phase 1:6
Phase 2:4
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (50.0%)
Phase 2
4 (33.3%)
Not Applicable
1 (8.3%)
Phase 3
1 (8.3%)

A Study of Laquinimod Eye-drops in Healthy Participants

Phase 1
Completed
Conditions
Eye Diseases
Interventions
Drug: Placebo
First Posted Date
2022-01-11
Last Posted Date
2023-01-31
Lead Sponsor
Active Biotech AB
Target Recruit Count
54
Registration Number
NCT05187403
Locations
🇦🇹

Clinical trial center at Medical University Vienna, Vienna, Austria

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)

Phase 2
Completed
Conditions
Systemic Sclerosis
Interventions
First Posted Date
2011-12-07
Last Posted Date
2014-08-27
Lead Sponsor
Active Biotech AB
Target Recruit Count
9
Registration Number
NCT01487551

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: Placebo
First Posted Date
2010-11-04
Last Posted Date
2015-10-21
Lead Sponsor
Active Biotech AB
Target Recruit Count
1245
Registration Number
NCT01234311

A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-01-13
Last Posted Date
2014-08-27
Lead Sponsor
Active Biotech AB
Target Recruit Count
6
Registration Number
NCT01048203
Locations
🇸🇪

JJ Berzelius Clinical Research Center AB, Berzelius Science Park, Linköping, Sweden

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
First Posted Date
2009-10-19
Last Posted Date
2015-06-25
Lead Sponsor
Active Biotech AB
Target Recruit Count
13
Registration Number
NCT00997100
Locations
🇩🇰

Soren Jacobsen, Copenhagen, Denmark

🇸🇪

Dept of Rheumatology, University Hospital in Lund, Lund, Sweden

🇸🇪

Iva Gunnarsson M.D., Stockholm, Sweden

and more 1 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.